In both breast cancer cell lines, Epo + LFM-A13 treatment resulted in S phase fraction reduction with a significant 40 and 45% decrease in the number of cells in MCF-7 and MDA-MB-231, respectively. The gene discussed is EPO; the disease is breast carcinoma.